| [1] | Ballard C, Waite J, Birks J (2006) Atypical antipsychotics for aggression and psychosis in Alzheimer's disease. Cochrane Database of Systematic Reviews 2006: Art. No.: CD003476. DOI:003410.001002/14651858.CD14003476.pub146？51852.
|
| [2] | Brambilla F, Monteleone P, Maj M (2007) Olanzapine-induced weight gain in anorexia nervosa: Involvement of leptin and ghrelin secretion? Psychoneuroendocrinology 32: 402–406.
|
| [3] | Bridle C, Palmer S, Bagnall AM, Darba J, Duffy S, et al. (2004) A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder. Health Technol Assess 8: iii–iv.
|
| [4] | Budman C, Gayer A, Lesser M, Shi Q, Bruun R (2001) An open-label study of the treatment efficacy of olanzapine for Tourette's disorder. J Clin Psychiatry 62: 290–294.
|
| [5] | Centorrino F, Eakin M, Bahk W-M, Kelleher JP, Goren J, et al. (2002) Inpatient Antipsychotic Drug Use in 1998, 1993, and 1989. Am J Psychiatry 159: 1932–1935.
|
| [6] | De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU (2011) Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiat 26: 144–158.
|
| [7] | Frenchman IB (2005) Atypical antipsychotics for nursing home patients: a retrospective chart review. Drugs & Aging 22: 257–264.
|
| [8] | Pickar D, Vinik J, Bartko JJ (2008) Pharmacotherapy of Schizophrenic Patients: Preponderance of Off-Label Drug Use. PLoS ONE 3: e3150.
|
| [9] | Newcomer J (2005) Second-Generation Atypical Antipsychotics and Metabolic Effects. A Comprehensive Literature Review. CNS Drugs 19: 1–93.
|
| [10] | Eder U, Mangweth B, Ebenbichler C, Weiss E, Hofer A, et al. (2001) Association of olanzapine-induced weight gain with an increase in body fat. Am J Psych 158: 1719.
|
| [11] | Gothelf D, Falk B, Singer P, Kairi M, Phillip M, et al. (2002) Weight Gain Associated With Increased Food Intake and Low Habitual Activity Levels in Male Adolescent Schizophrenic Inpatients Treated With Olanzapine. Am J Psychiatry 159: 1055–1057.
|
| [12] | Ryan MCM, Flanagan S, Kinsella U, Keeling F, Thakore JH (2004) The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci 74: 1999–2008.
|
| [13] | Zhang Z-J, Yao Z-J, Liu WEN, Fang QUN, Reynolds GP (2004) Effects of antipsychotics on fat deposition and changes in leptin and insulin levels: Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 184: 58–62.
|
| [14] | Allison DB, Newcomer JW, Dunn AL, Blumenthal JA, Fabricatore AN, et al. (2009) Obesity Among Those with Mental Disorders: A National Institute of Mental Health Meeting Report. Am J Prev Med 36: 341–350.
|
| [15] | Brown S, Birtwistle J, Roe L, Thompson C (1999) The unhealthy lifestyle of people with schizophrenia. Psychol Med 29: 697–701.
|
| [16] | Archie S, Wilson J, Osborne S, Hobbs H, McNiven J (2003) Pilot study: access to fitness facility and exercise levels in olanzapine-treated patients. Can J Psychiatry 48: 628–632.
|
| [17] | Rader DJ (2007) Effect of Insulin Resistance, Dyslipidemia, and Intra-abdominal Adiposity on the Development of Cardiovascular Disease and Diabetes Mellitus. Am J Med 120: S12–S18.
|
| [18] | Weiden PJ, Mackell JA, McDonnell DD (2004) Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 66: 51–57.
|
| [19] | Coccurello R, Moles A (2010) Potential mechanisms of atypical antipsychotic-induced metabolic derangement: Clues for understanding obesity and novel drug design. Pharmacol Ther 127: 210–251.
|
| [20] | Starrenburg FCJ, Bogers JPAM (2009) How can antipsychotics cause diabetes mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins. Eur Psychiat 24: 164–170.
|
| [21] | Reynolds GP, Kirk SL (2010) Metabolic side effects of antipsychotic drug treatment - pharmacological mechanisms. Pharmacol Ther 125: 169–179.
|
| [22] | Deng C, Weston-Green K, Huang X-F (2010) The role of histaminergic H1 and H3 receptors in food intake: A mechanism for atypical antipsychotic-induced weight gain? Prog Neuropsychopharmacol Biol Psychiatry 34: 1–4.
|
| [23] | Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH (2007) Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proceedings of the National Academy of Sciences 104: 3456–3459.
|
| [24] | Kirk S, Glazebrook J, Grayson B, Neill J, Reynolds G (2009) Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors. Psychopharmacology 207: 119–125.
|
| [25] | Matsui-Sakata A, Ohtani H, Sawada Y (2005) Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metabolism and Pharmacokinetics 20: 368–378.
|
| [26] | Nasrallah H (2008) Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiat 13: 27–35.
|
| [27] | Berthoud H-R (2002) Multiple neural systems controlling food intake and body weight. Neurosci Biobehav Rev 26: 393–428.
|
| [28] | Broberger C, H？kfelt T (2001) Hypothalamic and vagal neuropeptide circuitries regulating food intake. Physiol Behav 74: 669–682.
|
| [29] | Faulconbridge LF, Grill HJ, Kaplan JM, Daniels D (2008) Caudal brainstem delivery of ghrelin induces fos expression in the nucleus of the solitary tract, but not in the arcuate or paraventricular nuclei of the hypothalamus. Brain Res 1218: 151–157.
|
| [30] | Derbenev AV, Stuart TC, Smith BN (2004) Cannabinoids suppress synaptic input to neurones of the rat dorsal motor nucleus of the vagus nerve. J Physiol (Lond) 559: 923–938.
|
| [31] | Berrendero F, Romero J, García-Gil L, Suarez I, De la Cruz P, et al. (1998) Changes in cannabinoid receptor binding and mRNA levels in several brain regions of aged rats. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1407: 205–214.
|
| [32] | Bermudez-Silva FJ, Viveros MP, McPartland JM, Rodriguez de Fonseca F (2010) The endocannabinoid system, eating behavior and energy homeostasis: The end or a new beginning? Pharmacol Biochem Behav 95: 375–382.
|
| [33] | Tiwari AK, Zai CC, Likhodi O, Lisker A, Singh D, et al. (2010) A Common Polymorphism in the Cannabinoid Receptor 1 (CNR1) Gene is Associated with Antipsychotic-Induced Weight Gain in Schizophrenia. Neuropsychopharmacology 35: 1315–1324.
|
| [34] | Secher A, Husum H, Holst B, Egerod KL, Mellerup E (2010) Risperidone Treatment Increases CB1 Receptor Binding in Rat Brain. Neuroendocrinology 91: 155.
|
| [35] | Weston-Green K, Huang X-F, Han M, Deng C (2008) The effects of antipsychotics on the density of cannabinoid receptors in the dorsal vagal complex of rats: implications for olanzapine-induced weight gain. Int J Neuropsychopharmacol 11: 827–835.
|
| [36] | Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74: 129–180.
|
| [37] | Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, et al. (2005) Identification and Functional Characterization of Brainstem Cannabinoid CB2 Receptors. Science 310: 329–332.
|
| [38] | Meeker RB, Myers RD (1980) GABA and glutamate: Possible metabolic intermediaries involved in the hypothalamic regulation of food intake. Brain Res Bull 5: 253–259.
|
| [39] | Vong L, Ye C, Yang Z, Choi B, Chua S, et al. (2011) Leptin Action on GABAergic Neurons Prevents Obesity and Reduces Inhibitory Tone to POMC Neurons. Neuron 71: 142–154.
|
| [40] | Meister B (2007) Neurotransmitters in key neurons of the hypothalamus that regulate feeding behavior and body weight. Physiol Behav 92: 263–271.
|
| [41] | Akbarian S, Huang H-S (2006) Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders. Brain Research Reviews 52: 293–304.
|
| [42] | Kaufman DL, Houser CR, Tobin AJ (1991) Two Forms of the γ-Aminobutyric Acid Synthetic Enzyme Glutamate Decarboxylase Have Distinct Intraneuronal Distributions and Cofactor Interactions. J Neurochem 56: 720–723.
|
| [43] | Esclapez M, Tillakaratne NJ, Kaufman DL, Tobin AJ, Houser CR (1994) Comparative localization of two forms of glutamic acid decarboxylase and their mRNAs in rat brain supports the concept of functional differences between the forms. J Neurosci 14: 1834–1855.
|
| [44] | Martin DL, Rimvall K (1993) Regulation of γ-Aminobutyric Acid Synthesis in the Brain. J Neurochem 60: 395–407.
|
| [45] | Feldblum S, Erlander MG, Tobin AJ (1993) Different distributions of GAD65 and GAD67 mRNAS suggest that the two glutamate decarboxylases play distinctive functional roles. J Neurosci Res 34: 689–706.
|
| [46] | Schwartz MW, Woods SC, Porte D, Seeley RJ, Baskin DG (2000) Central nervous system control of food intake. Nature 404: 661–671.
|
| [47] | Bronstein DM, Schafer MKH, Watson SJ, Akil H (1992) Evidence that [beta]-endorphin is synthesized in cells in the nucleus tractus solitarius: detection of POMC mRNA. Brain Res 587: 269–275.
|
| [48] | Wai S, Kindler P, Lam E, Zhang A, Yew D (2004) Distribution of neuropeptide Y-immunoreactive neurons in the human brainstem, cerebellum, and cortex during development. Cell Mol Neurobiol 24: 667–684.
|
| [49] | Wu Q, Palmiter RD (2011) GABAergic signaling by AgRP neurons prevents anorexia via a melanocortin-independent mechanism. Eur J Pharmacol 660: 21–27.
|
| [50] | Beck B (2006) Neuropeptide Y in normal eating and in genetic and dietary-induced obesity. Philosophical Transactions of the Royal Society B: Biological Sciences 361: 1159–1185.
|
| [51] | Heilig M, Murison R (1987) Intracerebroventricular neuropeptide Y suppresses open field and home cage activity in the rat. Regul Pept 19: 221–231.
|
| [52] | Heilig M, Wahlestedt C, Widerl？v E (1988) Neuropeptide Y (NPY)-induced suppression of activity in the rat: evidence for NPY receptor heterogeneity and for interaction with [alpha]-adrenoceptors. Eur J Pharmacol 157: 205–213.
|
| [53] | Beck B, Strickerkrongrad A, Nicolas JP, Burlet C (1992) Chronic and continuous intracerebroventricular infusion of Neuropeptide-Y in Long-Evans rats mimics the feeding-behavior of obese Zucker rats. Int J Obes 16: 295–302.
|
| [54] | Stanley BG, Kyrkouli SE, Lampert S, Leibowitz SF (1986) Neuropeptide Y chronically injected into the hypothalamus: A powerful neurochemical inducer of hyperphagia and obesity. Peptides 7: 1189–1192.
|
| [55] | Obuchowicz E (1996) Long-term treatment with chlorpromazine and haloperidol but not with sulpiride and clozapine markedly elevates neuropeptide Y-like immunoreactivity in the rat hypothalamus. Neuropeptides 30: 471–478.
|
| [56] | Kirk SL, Cahir M, Reynolds GP (2006) Clozapine, but not haloperidol, increases neuropeptide Y neuronal expression in the rat hypothalamus. J Psychopharmacol (Oxf) 20: 577–579.
|
| [57] | Baptista T, Araujo de Baptista E, Ying Kin NMKN, Beaulieu S, Walker D, et al. (2002) Comparative effects of the antipsychotics sulpiride or risperidone in rats: I: Bodyweight, food intake, body composition, hormones and glucose tolerance. Brain Res 957: 144–151.
|
| [58] | Pouzet B, Mow T, Kreilg？rd M, Velschow S (2003) Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. Pharmacol Biochem Behav 75: 133–140.
|
| [59] | Minet-Ringuet J, Even PC, Goubern M, Tomé D, de Beaurepaire R (2006) Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration. Appetite 46: 254–262.
|
| [60] | Minet-Ringuet J, Even PC, Guesdon B, Tomé D, de Beaurepaire R (2005) Effects of chronic neuroleptic treatments on nutrient selection, body weight, and body composition in the male rat under dietary self-selection. Behav Brain Res 163: 204–211.
|
| [61] | Obuchowicz E, Krysiak R, Wieronska JM, Smialowska M, Herman ZS (2005) Alterations in striatal neuropeptide Y system activity of rats with haloperidol-induced behavioral supersensitivity. Neuropeptides 39: 515–523.
|
| [62] | Obuchowicz E, Turchan J (1998) Influence of typical and atypical antipsychotics on neuropeptide Y-like immunoreactivity and NPY mRNA expression in rat striatum. Neuropeptides 32: 473–480.
|
| [63] | Obuchowicz E, Turchan J (1999) Clozapine decreases neuropeptide Y-like immunoreactivity and neuropeptide Y mRNA levels in rat nucleus accumbens. Eur Neuropsychopharmacol 9: 329–335.
|
| [64] | Obuchowicz E, Krysiak R, Herman ZS (2004) Does neuropeptide Y (NPY) mediate the effects of psychotropic drugs? Neurosci Biobehav Rev 28: 595–610.
|
| [65] | Huang XF, Deng C, Zavitsanou K (2006) Neuropeptide Y mRNA expression levels following chronic olanzapine, clozapine and haloperidol administration in rats. Neuropeptides 40: 213–219.
|
| [66] | Ferno J, Varela L, Skrede S, Vazquez MJ, Nogueiras R, et al. (2011) Olanzapine-Induced Hyperphagia and Weight Gain Associate with Orexigenic Hypothalamic Neuropeptide Signaling without Concomitant AMPK Phosphorylation. PLoS ONE 6: e20571.
|
| [67] | Davoodi N, Kalinichev M, Korneev S, Clifton P (2009) Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine. Psychopharmacology 203: 693–702.
|
| [68] | Ota M, Mori K, Nakashima A, Kaneko Y, Fujiwara K, et al. (2002) Peripheral injection of risperidone, an atypical antipsychotic, alters the bodyweight gain of rats. Clin Exp Pharmacol Physiol 29: 980–989.
|
| [69] | Hartfield A, Moore N, Clifton P (2003) Effects of clozapine, olanzapine and haloperidol on the microstructure of ingestive behaviour in the rat. Psychopharmacology 167: 115.
|
| [70] | Weston-Green K, Huang X-F, Deng C (2011) Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats. Behav Brain Res 217: 337–346.
|
| [71] | Nemeroff C (1997) Dosing the antipsychotic medication olanzapine. J Clin Psychiatry 58: 45–49.
|
| [72] | Albaugh V, Henry C, Bello N, Hajnal A, Lynch S, et al. (2006) Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obesity 14: 36–50.
|
| [73] | Cope MB, Nagy TR, Fernandez JR, Geary N, Casey DE, et al. (2005) Antipsychotic drug-induced weight gain: development of an animal model. Int J Obes Relat Metab Disord 29: 607–614.
|
| [74] | Kapur S, VanderSpek SC, Brownlee BA, Nobrega J (2003) Antipsychotic Dosing in Preclinical Models Is Often Unrepresentative of the Clinical Condition: A Suggested Solution Based on in Vivo Occupancy. J Pharmacol Exp Ther 305: 625–631.
|
| [75] | Aravagiri M, Teper Y, Marder SR (1999) Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm Drug Dispos 20: 369–377.
|
| [76] | Tauscher J, Jones C, Remington G, Zipursky R, Kapur S (2002) Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiat 7: 317–321.
|
| [77] | Kapur S, Wadenberg ML, Remington G (2000) Are animal studies of antipsychotics appropriately dosed? Lessons from the bedside to the bench. Canadian Journal Of Psychiatry Revue Canadienne De Psychiatrie 45: 241–246.
|
| [78] | Deng C, Weston-Green KL, Han M, Huang X-F (2007) Olanzapine treatment decreases the density of muscarinic M2 receptors in the dorsal vagal complex of rats. Prog Neuropsychopharmacol Biol Psychiatry 31: 915–920.
|
| [79] | Han M, Deng C, Burne THJ, Newell KA, Huang X-F (2008) Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression. Psychoneuroendocrinology 33: 569–580.
|
| [80] | Huang X-F, Han M, Huang X, Zavitsanou K, Deng C (2006) Olanzapine differentially affects 5-HT2A and 2C receptor mRNA expression in the rat brain. Behav Brain Res 171: 355–362.
|
| [81] | Reagan-Shaw S, Nihal M, Ahmad N (2007) Dose translation from animal to human studies revisited. The FASEB Journal 22: 659–661.
|
| [82] | Lin S, Storlien LH, Huang X-F (2000) Leptin receptor, NPY, POMC mRNA expression in the diet-induced obese mouse brain. Brain Res 875: 89–95.
|
| [83] | Ling LL, Hughes LF, Caspary DM (2005) Age-related loss of the GABA synthetic enzyme glutamic acid decarboxylase in rat primary auditory cortex. Neuroscience 132: 1103–1113.
|
| [84] | Deng C, Han M, Huang X (2007) No changes in densities of cannabinoid receptors in the superior temporal gyrus in schizophrenia. Neurosci Bull 23: 341–347.
|
| [85] | Paxinos G, Watson C (2007) The Rat Brain in Stereotaxic Coordinates. CA, USA: Elselvier Academic Press Inc.
|
| [86] | Kim E-M, O'Hare E, Grace MK, Welch CC, Billington CJ, et al. (2000) ARC POMC mRNA and PVN [alpha]-MSH are lower in obese relative to lean Zucker rats. Brain Res 862: 11–16.
|
| [87] | Guan X-M, Yu H, Van der Ploeg LHT (1998) Evidence of altered hypothalamic pro-opiomelanocortin/neuropeptide Y mRNA expression in tubby mice. Mol Brain Res 59: 273–279.
|
| [88] | Huang X-F, Han M, South T, Storlien L (2003) Altered levels of POMC, AgRP and MC4-R mRNA expression in the hypothalamus and other parts of the limbic system of mice prone or resistant to chronic high-energy diet-induced obesity. Brain Res 992: 9–19.
|
| [89] | Krude H, Biebermann H, Luck W, Horn R, Brabant G, et al. (1998) Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 19: 155–157.
|
| [90] | Martin NM, Small CJ, Sajedi A, Liao XH, Weiss RE, et al. (2004) Abnormalities of the hypothalamo-pituitary-thyroid axis in the pro-opiomelanocortin deficient mouse. Regul Pept 122: 169–172.
|
| [91] | Cone R (2005) Anatomy and regulation of the central melanocortin system. Nat Neurosci 8: 571–578.
|
| [92] | Meister B, G？mü？ B, Suarez E, Ishii Y, Dürr K, et al. (2006) Hypothalamic proopiomelanocortin (POMC) neurons have a cholinergic phenotype. Eur J Neurosci 24: 2731–2740.
|
| [93] | Zhang Y, Rodrigues E, Gao YX, King M, Cheng KY, et al. (2010) Pro-opiomelanocortin gene transfer to the nucleus of the solitary track but not arcuate nucleus ameliorates chronic diet-induced obesity. Neuroscience 169: 1662–1671.
|
| [94] | Ste Marie L, Luquet S, Cole T, Palmiter R (2005) Modulation of neuropeptide Y expression in adult mice does not affect feeding. Proc Natl Acad Sci U S A 102: 18632–18637. Epub 12005 Dec 18638:
|
| [95] | Erickson JC, Clegg KE, Palmiter RD (1996) Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature 381: 415–418.
|
| [96] | Hollopeter G, Erickson JC, Seeley RJ, Marsh DJ, Palmiter RD (1998) Response of neuropeptide Y-deficient mice to feeding effectors. Regul Pept 75–76: 383–389.
|
| [97] | Lin S, Boey D, Herzog H (2004) NPY and Y receptors: lessons from transgenic and knockout models. Neuropeptides 38: 189–200.
|
| [98] | Cowley MA, Smart JL, Rubinstein M, Cerdan MG, Diano S, et al. (2001) Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature 411: 480.
|
| [99] | Csiffa'ry A, G？rcs TJ, Palkovits M (1990) Neuropeptide Y innervation of ACTH-immunoreactive neurons in the arcuate nucleus of rats: a correlated light and electron microscopic double immunolabeling study. Brain Res 506: 215–222.
|
| [100] | Roseberry AG, Liu H, Jackson AC, Cai X, Friedman JM (2004) Neuropeptide Y-Mediated Inhibition of Proopiomelanocortin Neurons in the Arcuate Nucleus Shows Enhanced Desensitization in ob/ob Mice. Neuron 41: 711–722.
|
| [101] | Qian S, Chen H, Weingarth D, Trumbauer ME, Novi DE, et al. (2002) Neither Agouti-Related Protein nor Neuropeptide Y Is Critically Required for the Regulation of Energy Homeostasis in Mice. Molecular Cell Biology 22: 5027–5035.
|
| [102] | Gropp E, Shanabrough M, Borok E, Xu AW, Janoschek R, et al. (2005) Agouti-related peptide-expressing neurons are mandatory for feeding. Nat Neurosci 8: 1289–1291.
|
| [103] | Tong Q, Ye C-P, Jones JE, Elmquist JK, Lowell BB (2008) Synaptic release of GABA by AgRP neurons is required for normal regulation of energy balance. Nat Neurosci 11: 998–1000.
|
| [104] | Hentges ST, Nishiyama M, Overstreet LS, Stenzel-Poore M, Williams JT, et al. (2004) GABA Release from Proopiomelanocortin Neurons. J Neurosci 24: 1578–1583.
|
| [105] | Horvath TL, Bechmann I, Naftolin F, Kalra SP, Leranth C (1997) Heterogeneity in the neuropeptide Y-containing neurons of the rat arcuate nucleus: GABAergic and non-GABAergic subpopulations. Brain Res 756: 283–286.
|
| [106] | Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, et al. (2004) Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 47: 345–358.
|
| [107] | Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, et al. (2001) Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410: 822–825.
|
| [108] | Alger BE (2002) Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. Progress in Neurobiology 68: 247–286.
|
| [109] | Wilson RI, Nicoll RA (2002) Endocannabinoid signaling in the brain. (Review: Neuroscience). Science 296: 678(675).
|
| [110] | Hentges ST, Low MJ, Williams JT (2005) Differential Regulation of Synaptic Inputs by Constitutively Released Endocannabinoids and Exogenous Cannabinoids. J Neurosci 25: 9746–9751.
|
| [111] | Nguyen Q, Wagner E (2007) Estrogen differentially modulates the cannabinoid- induced presynaptic inhibition of amino acid neurotransmission in proopiomelanocortin neurons of the arcuate nucleus. Neuroendocrinology 84: 123.
|
| [112] | Menzies JRW, Ludwig M, Leng G (2010) Direct and Indirect Effects of Cannabinoids on in vitro GABA Release in the Rat Arcuate Nucleus. J Neuroendocrinol 22: 585–592.
|
| [113] | Gamber KM, Macarthur H, Westfall TC (2005) Cannabinoids augment the release of neuropeptide Y in the rat hypothalamus. Neuropharmacology 49: 646–652.
|
| [114] | Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, et al. (2003) H1-Histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28: 519–526.
|
| [115] | Richelson E, Souder T (2000) Binding of antipsychotic drugs to human brain receptors: Focus on newer generation compounds. Life Sci 68: 29–39.
|
| [116] | Yoshimatsu H (2006) The neuronal histamine H1 and pro-opiomelanocortin-melanocortin 4 receptors: Independent regulation of food intake and energy expenditure. Peptides 27: 326–332.
|
| [117] | Kuo D-Y (2002) Co-administration of dopamine D1 and D2 agonists additively decreases daily food intake, body weight and hypothalamic neuropeptide Y level in rats. J Biomed Sci 9: 126–132.
|
| [118] | Kuo D-Y (2006) Hypothalamic neuropeptide Y (NPY) and the attenuation of hyperphagia in streptozotocin diabetic rats treated with dopamine D1/D2 agonists. British Journal of Pharmacology 148: 640–647.
|
| [119] | Pelletier G, Simard J (1991) Dopaminergic regulation of pre-proNPY mRNA levels in the rat arcuate nucleus. Neurosci Lett 127: 96–98.
|
| [120] | Heisler LK, Cowley MA, Tecott LH, Fan W, Low MJ, et al. (2002) Activation of Central Melanocortin Pathways by Fenfluramine. Science 297: 609–611.
|
| [121] | Qiu J, Xue C, Bosch MA, Murphy JG, Fan W, et al. (2007) Serotonin 5-Hydroxytryptamine2C Receptor Signaling in Hypothalamic Proopiomelanocortin Neurons: Role in Energy Homeostasis in Females. Mol Pharmacol 72: 885–896.
|
| [122] | Bymaster F, Calligaro D, Falcone J, Marsh R, Moore N, et al. (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14: 87–96.
|
| [123] | Bymaster F, Hemrick-Luecke S, Perry K, Fuller R (1996) Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology 124: 87–94.
|
| [124] | Xu B, Kalra PS, Farmerie WG, Kalra SP (1999) Daily Changes in Hypothalamic Gene Expression of Neuropeptide Y, Galanin, Proopiomelanocortin, and Adipocyte Leptin Gene Expression and Secretion: Effects of Food Restriction. Endocrinology 140: 2868–2875.
|
| [125] | Nasrallah H (2003) A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 28: 83–96.
|
| [126] | NIMH Psychoactive Drug Screening Program website. Available: http://pdsp.med.unc.edu/kidb.php. Accessed 2011 Oct 20.
|
| [127] | Roth B, Kroeze W, Patel S, Lopez E (2000) The Multiplicity of Serotonin Receptors: Uselessly diverse molecules or an embarrassment of riches? The Neuroscientist 6: 252–262.
|
| [128] | Li C, Jones PM, Persaud SJ (2011) Role of the endocannabinoid system in food intake, energy homeostasis and regulation of the endocrine pancreas. Pharmacol Ther 129: 307–320.
|
| [129] | Cavuoto P, Wittert GA (2009) The role of the endocannabinoid system in the regulation of energy expenditure. Best Pract Res Cl En 23: 79–86.
|
| [130] | Nogueiras R, Diaz-Arteaga A, Lockie SH, Velásquez DA, Tschop J, et al. (2009) The endocannabinoid system: Role in glucose and energy metabolism. Pharmacol Res 60: 93–98.
|
| [131] | Harrold J, Williams G (2003) The cannabinoid system: a role in both the homeostatic and hedonic control of eating? Br J Nutr 90: 729–734.
|
| [132] | Kirkham TC (2009) Cannabinoids and appetite: Food craving and food pleasure. Int Rev Psychiatr 21: 163–171.
|
| [133] | Gomez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, et al. (2002) A Peripheral Mechanism for CB1 Cannabinoid Receptor-Dependent Modulation of Feeding. J Neurosci 22: 9612–9617.
|
| [134] | Cota D, Marsicano G, Tschop M, Glubler Y, Flachskamm C, et al. (2003) The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112: 423–431.
|
| [135] | Sharkey KA, Pittman QJ (2005) Central and Peripheral Signaling Mechanisms Involved in Endocannabinoid Regulation of Feeding: A Perspective on the Munchies. Sci STKE pe15.
|
| [136] | Kirkham T (2008) Endocannabinoids and the neurochemistry of gluttony. J Neuroendocrinol 20: 1099–1100.
|
| [137] | Balcombe J, Barnard N, Sandusky C (2004) Laboratory routines cause animal stress. Contemp Top Lab Anim 43: 42–51.
|
| [138] | Remington G, Mann S, McCormick P, Nobrega JN, Hahn M, et al. (2011) Modeling chronic olanzapine exposure using osmotic minipumps: Pharmacological limitations. Pharmacology Biochemistry and Behavior 100: 86–89.
|
| [139] | van der Zwaal EM, Luijendijk MCM, Adan RAH, la Fleur SE (2008) Olanzapine-induced weight gain: Chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution. Eur J Pharmacol 585: 130–136.
|
| [140] | de Meijer VE, Le HD, Meisel JA, Puder M (2010) Repetitive orogastric gavage affects the phenotype of diet-induced obese mice. Physiol Behav 100: 387–393.
|
| [141] | Beasley JCM, Tollefson G, Tran P, Satterlee W, Sanger T, et al. (1996) Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14: 111–123.
|
